Member Info for MIKODX

Lol it sure did.

Dropping like a stone. Profits are shrinking. Do I get out now, or do I wait for the rerate, that's if it rerates? This was 5 yesterday, it's taken an almighty tumble today.

Stick a fork in it and move on. This outfit couldn't run a bath. Bunch of amateurs.

Just popping my head in. Not surprisingly, nothing to see here. Worst share on the planet.

I learned a long time ago, especially with growing stocks like PAF, never to use stop/losses. There will always be times when you get big drops, last thing you want is to have a stop loss in place that gets triggered. If the stock is bullish, it will always recover. If your the type of person that categorically must have stop/losses in place, then you will have to set it low enough to absorb any wild drops. Any higher and you will find yourself out of the game with little to show for it.

Gold took a hammering last week, it took a massive nosedive which has had a negative affect on the SP. This week has seen the first signs of rcovery with an 8% rise. If it continues, the SP should rerate back, then resume it's steady climb. Gold is very volatile at the minute

Need some good news and soon, must be some type of update on how things are progressing with Tempus. Any good news on that front should get the SP up a few ticks.

This type of bureaucracy has always been the problem for companies providing the technology. It slows down expansion and causes delays in adoption. A previous company I was invested in named Omega Diagnostics now known as Cambridge Nutritional Health, went through a similiar thing with the NHS during the covid years. In the end the company ended up taking the NHS to court and winning there case. Dealing with the NHS is a very slow process. However, in the case of Genedrive, the small steps have already been taken, the company have their feet firmly in the door. Wont be long before production and adoption increases on a much larger scale than recently. Recent figures show steady positive increases in the number of hospitals adopting the technology. The only way is up from here.

The way it smashed through five, this just could be only the beginning. Could see highs of ten years ago. Onwards and Up.

Deadstock. Get out while you can. Bankruptcy looming.

4.90 proving a hard nut to crack.

With the debt facility and revolving credit all sorted out, as well as the funds now readily available to Sidara, this should be wrapped up very soon. Just a matter of dotting the I’s and crossing the C’s now. Holding firmly.

Yes, but still means heavy dilution.

Futurehire - I bet this goes to 29p up until and during the court hearing. Would you still believe it's not manipulation then? I agree with GRaff, Sidara will be hoovering up the remaining shares now, although I think that maybe illegal, I'm sure there's plenty ways to get around that.

I was able to get in for 21p. Tempted to sell now as I cant be bothered to wait as who knows how long this could take, but profits will shrink if I do.. They said it should happen Q1 2026, but they always keep extending it. I'll give it another month and see what happens.

You see it, market manipulation at it's finest. As we get closer to the final stages of the takeover, the SP goes up. They make it so that it's not worth buying in as the profits are too small, and they make it high enough so that investors are tempted to sell at a lower price than the buyout price. Win win for Sidara, lose lose for investors. Total manipulation.

It's doing what all stocks do, they go up and down. Fundamentals hasn't changed so no cause for panic. Maybe just profit taking from previous highs.

Todays RNS means we are now seeing concrete progress on commercial rollout.This shows that Renalytix is moving towards actual deployment with multiple provider groups. Getting kidneyintelX.dkd into established clinics is a big step. It means providers see enough value in the test to integrate it into their day-to-day systems.

The RNS reiterates that Renalytix and Tempus are working closely to integrate kidneyintelX.dkd into larger healthcare sytems that are already on Tempus's platform. This is very significant because a) smaller clinics alone won't generate high volumes and b) larger sytems (via Tempus) have broader patient populations and infrastucture. This will accelerate adoption more rapidly once it starts rolling through those network. Everything is starting to fall into place, the company is really now starting to see some real progression. Great RNS.

The company says it expects to provide a fuller trading update in February. By fuller that means they expect improvement in sales. The company is making all the right moves thus far.

Lol, doesn't look like it this morning.